Even modest post-infection complications can make expanded vaccine coverage cost-effective, modeling suggests

by University of British Columbia

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

New modeling led by interdisciplinary scientists at the University of British Columbia (UBC) could help public health officials better factor in the long-term impacts of infectious disease when determining optimal vaccine coverage rates.

"Our models indicate even small post-infection costs can tip the scales and make the case for vaccine-driven elimination," said Dr. Chadi Saad-Roy, an assistant professor in UBC's Department of Mathematics and Department of Microbiology and Immunology and senior author of the new study, published in the Proceedings of the National Academy of Sciences.

The COVID-19 pandemic highlighted how the effects of an infection can linger, with more than 400 million people globally experiencing persistent symptoms ("long COVID"). While evidence of post-viral impacts is mounting, models that evaluate infectious disease management strategies typically focus only on the acute phase.

Balancing vaccination costs and lasting illness

To address this gap in the current study, the researchers developed a system of mathematical equations to examine interactions between interventions and post-infection effects.

"From the perspective of society, there's some cost to producing vaccines, and there's a big benefit to reducing infections and post-infection effects. So, the question is: Where does this optimum happen?" said Saad-Roy. For a benign virus, it may not be worth it to vaccinate at all.

For other infections, it may be best to vaccinate enough people to eliminate the disease. Or the ideal point may fall somewhere in between. "Our modeling can help answer those questions."

Transmission controls reduce long-term disease burden

The team first used an epidemiological model that calculates the fraction of susceptible, infectious and recovered individuals to evaluate nonpharmaceutical interventions that reduce transmission (such as masking, social distancing and air filtration) as a complement to vaccines.

They found that, on long timescales, nonpharmaceutical interventions substantially decreased the proportion of people who became infected and then recovered—and were therefore vulnerable to post-infection effects—suggesting that these measures can effectively reduce long-term disease burden.

Small post-infection costs shift vaccination targets

Next, the researchers coupled epidemiological and economic models to assess how the cost associated with post-recovery syndromes affects the optimal level of vaccine coverage.

To provide a tool that can pinpoint this sweet spot, the researchers wrote equations that account for the societal cost of acute and long-term infection (e.g., cost of hospitalization and loss of labor force) and the cost of vaccination in terms of development, production, distribution and recruitment.

They looked at three different vaccine cost scenarios as the number of vaccines given increases: one in which cost accelerates (assumes that there is a first wave of easy-to-reach vaccine adopters and that it becomes harder to vaccinate additional people due to vaccine hesitancy or logistical barriers), one in which cost decelerates (assumes that while there is initial resistance to vaccination, influence from peers makes it easier to vaccinate additional individuals) and one in which cost alternately accelerates and decelerates.

The team found that, in all scenarios, the ideal amount of vaccine coverage was very sensitive to post-acute effects and that even small post-infection costs could shift the optimal coverage to higher rates and even to elimination levels.

Tracking symptoms and reducing vaccine hesitancy

"We need to tackle this rigorously and not dismiss individuals' experiences as anecdotal," said Saad-Roy. To more systematically monitor and document post-infection effects, researchers may conduct large, long-term cohort studies that survey participants on a broad constellation of symptoms.

"These strategies can effectively reduce acute infection, which in turn mitigates post-acute burden and ultimately leads to a healthier world."

It's critical to understand which vaccine cost scenario—accelerating or decelerating—is at play in a specific setting to determine the optimal coverage level. This will require socioeconomic studies that explore vaccine decision-making dynamics in a given time and place, which may be influenced by outreach efforts.

"If we can educate people about the benefits of vaccination and reduce hesitancy, that can lower the cost of vaccination and tip the balance in favor of vaccinating to eliminate the disease," said Prakhar Jaiswal, a graduate student in the UBC Department of Mathematics and first author of the study.

The interdisciplinary team includes co-authors Daniel Coombs (UBC Mathematics), Caroline Wagner (McGill Bioengineering) and Troy Day (Queen's Mathematics & Statistics).

Publication details

Saad-Roy, Chadi M., Interventions to mitigate post-infection morbidity: Management insights from simple models, Proceedings of the National Academy of Sciences (2026). DOI: 10.1073/pnas.2609982123. doi.org/10.1073/pnas.2609982123

Journal information: Proceedings of the National Academy of Sciences

Key medical concepts

Vaccination

Clinical categories

Preventive medicineCommon illnesses & PreventionInfectious diseases Provided by University of British Columbia Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Even modest post-infection complications can make expanded vaccine coverage cost-effective, modeling suggests (2026, October 5) retrieved 5 October 2026 from https://medicalxpress.com/news/2026-10-modest-infection-complications-vaccine-coverage.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.